Scientific Programme

The course will provide a comprehensive update on the treatment of thoracic malignancies with special emphasis on the multimodality treatment. To that regard there is a wide participation of thoracic surgeons, chest physicians and oncologists.

At the end of the course participants will be able to:

– have a deeper knowledge of diagnostic modalities for thoracic malignancies

– be familiar with the most up to date form of treatment according to stage

– be able to choose and offer the patient several therapeutic modalities with an explanation of advantages and disadvantages

– be confident in drawing a treatment plan involving several specialists and treatment modalities (surgery, oncology and radiotherapy).

December 2, 2020

  • 14:30
    15:00

    Sponsor KOL video

  • 15:00
    15:15

    Start of the connection to the WEBINAR and opening

  • 15:15
    15:30

    Introduction to the course

MODULE I – EARLY DISEASE

I° SESSION

CHAIR: 

  • 15:30
    15:40

    Nelson study: what have we learnt and what is left to do?

  • 15:40
    15:50

    Radiologic diagnosis of lung cancer: when is it enough?

  • 15:50
    16:00

    New bronchoscopic techniques: friend or foe?

MODULE I – EARLY DISEASE

II° SESSION

CHAIR: 

  • 16:00
    16:10

    Resection vs surveillance for GGOs

  • 16:10
    16:20

    Surgery vs SBRT for operable patients: is there a role?

  • 16:20
    16:30

    Neoadjuvant treatments for early stage lung cancer: is there a role?

MODULE I – EARLY DISEASE

III° SESSION

CHAIR: 

  • 16:30
    16:40

    Where do we draw the line for indications for surgery? The truly inoperable patient

  • 16:40
    16:50

    Ecmo for thoracic surgery

  • 16:50
    17:00

    How much can we push minimally invasive surgery?

  • 17:00
    17:30

    Q&A

  • 17:30

    Closing the firs webinar module

  • 17:30
    18:00

    Sponsor KOL video

December 3, 2020

  • 14:30
    15:00

    Sponsor KOL video

  • 15:00
    15:15

    Start of the connection to the webinar

  • 15:15
    15:30

    Introduction to the course

MODULE II – ADVANCED DISEASE

I° SESSION

CHAIR: 

  • 15:30
    15:40

    Immunotherapy in resectable NSCLC

  • 15:40
    15:50

    News in immunotherapy world in advanced NSCLC: improving the bar

  • 15:50
    16:00

    Neoadjuvant strategies in oncogene addicted tumors: is it now the time?

MODULE II – ADVANCED DISEASE

II° SESSION

CHAIR:

  • 16:00
    16:10

    Oncogene addicted tumors: new OMA’s to know

  • 16:10
    16:20

    SCLC a new dawn or the same old refrain

  • 16:20
    16:30

    Concomitant neoadjuvant chemoRT vs neoadjuvant chemo vs surgery upfront

MODULE II – ADVANCED DISEASE

III° SESSION

CHAIR: 

  • 16:30
    16:40

    Treatment of (un)resactable stage III lung cancer

  • 16:40
    16:50

    Oligometastatic disease: when is too much for surgery?

  • 16:50
    17:00

    Multimodality approach for orphan diseases: MPM and SCLC

  • 17:00
    17:30

    Q&A

  • 17:30

    Closing of the webinar

  • 17:30
    18:00

    Sponsor KOL video

2/3 DECEMBER 2020 – MILANO

The multidisciplinary treatment of lung cancer